Albenatide vs aleniglipron

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline

Albenatide

Developed by ConjuChem and partners

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT07058545 · Phase 3 · completed

The study randomized 474 participants to CJC-1134-PC or placebo and blinded participants, care providers, investigators, and outcome assessors. Its primary endpoint was change in HbA1c at Week 25, a surrogate measure, and the registry does not report whether the comparison was favorable or statistically significant.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

No aligned efficacy figure on record for this race.

aleniglipron

Developed by Structure Therapeutics

Phase 3 in Type 2 Diabetessmall molecule
Weak signal

NCT05762471 · Phase 1/2 · completed

The study randomized 142 participants to GSBR-1290 or placebo with participants, care providers, and investigators masked. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Incidence, severity and relationship of AE/SAE, vital signs, laboratory measures and ECG to assess safety and tolerability of multiple oral doses of GSBR-1290 in HOV and T2DM". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Registered primary endpoint is safety/tolerability; the weight results are the phase 2a obesity cohort's efficacy readout from the sponsor's SEC-filed topline release, not yet peer reviewed.

Next expected readout: September 2028 · NCT07654374 (registry estimate)

Reported efficacy

Incidence, severity and relationship of AE/SAE, vital signs, laboratory measures and ECG to assess safety and tolerability of multiple oral doses of GSBR-1290 in HOV and T2DM (42 days): Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo (met)

Result source: NCT05762471

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlbenatidealeniglipron
HbA1c, change-0.8% vs -0.5%−0.4 vs placebo1.5 mg · wk 12.14 · n 44NCT00638716
1 other result
  • -1.3% vs -0.3% 1.5 mg · wk 12.14 · n 27 · Phase 2 · primary NCT00674466
—Trial running · NCT07654374
Body weight, change (kg)-2.0 vs -1.6−0.4 vs placebo1.5 mg · wk 12.14 · n 44NCT00638716
1 other result
  • -1.2 vs -0.4 1.5 mg · wk 12.14 · n 27 · Phase 2 · secondary NCT00674466
—Trial running · NCT07654374
HbA1c below 7%—Not posted · NCT07058545—Trial running · NCT07654374
Fasting plasma glucose, change-0.8 vs -0.6−0.2 vs placebo1.5 mg · wk 12.14 · n 42NCT00638716
1 other result
  • -0.3 vs 0.7 1.5 mg · wk 12.14 · n 27 · Phase 2 · secondary NCT00674466
—Trial running · NCT07654374
3-point MACE (% with event)—Not posted · NCT07058545—Trial running · NCT07654374

HbA1c, change

Albenatide
-0.8% vs -0.5%−0.4 vs placebo1.5 mg · wk 12.14 · n 44NCT00638716
1 other result
  • -1.3% vs -0.3% 1.5 mg · wk 12.14 · n 27 · Phase 2 · primary NCT00674466
aleniglipron
—Trial running · NCT07654374

Body weight, change (kg)

Albenatide
-2.0 vs -1.6−0.4 vs placebo1.5 mg · wk 12.14 · n 44NCT00638716
1 other result
  • -1.2 vs -0.4 1.5 mg · wk 12.14 · n 27 · Phase 2 · secondary NCT00674466
aleniglipron
—Trial running · NCT07654374

HbA1c below 7%

Albenatide
—Not posted · NCT07058545
aleniglipron
—Trial running · NCT07654374

Fasting plasma glucose, change

Albenatide
-0.8 vs -0.6−0.2 vs placebo1.5 mg · wk 12.14 · n 42NCT00638716
1 other result
  • -0.3 vs 0.7 1.5 mg · wk 12.14 · n 27 · Phase 2 · secondary NCT00674466
aleniglipron
—Trial running · NCT07654374

3-point MACE (% with event)

Albenatide
—Not posted · NCT07058545
aleniglipron
—Trial running · NCT07654374
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

aleniglipron
Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo NCT05762471 · Phase 1/2 · design grade: weak · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Albenatide: 3 of 4 rows · aleniglipron: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlbenatide
Dropout rate
14%1.5 mga
NCT00638716 · Phase 2 · registry result, not featured evidence
show 1 more result
23.3%1.5 mg
NCT00674466 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—1.5 mga
NCT00638716 · Phase 2 · registry result, not featured evidence
show 1 more result
—1.5 mg
NCT00674466 · Phase 2 · registry result, not featured evidence
Serious AEs
0%1.5 mga
NCT00638716 · Phase 2 · registry result, not featured evidence
show 1 more result
3.3%1.5 mg
NCT00674466 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
1.5 mga
nausea 22.4% (placebo 15.8%)
diarrhea 12.2% (placebo 5.3%)
vomiting 12.2% (placebo 3.5%)
NCT00638716 · Phase 2 · registry result, not featured evidence
show 1 more result
1.5 mg
headache 26.7% (placebo 24.1%)
nausea 26.7% (placebo 13.8%)
vomiting 23.3% (placebo 17.2%)
NCT00674466 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Albenatide

HbA1c -0.85% (n=44) vs -0.46% (n=47) placebo @ 12.14wk1.5 mg
absolute change · percentage points
NCT00638716 · Phase 2 · registry result, not featured evidence
show 1 more result
-1.29% (n=27) vs -0.34% (n=26) placebo @ 12.14wk1.5 mg
NCT00674466 · Phase 2 · registry result, not featured evidence
Fasting Plasma Glucose -0.75 vs -0.56 placebo mmol/L @ 12.14wk1.5 mg
absolute change · mmol/L
NCT00638716 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -13.48 mg/dL as posted
show 1 more result
-0.33 vs 0.67 placebo mmol/L @ 12.14wk*1.5 mg
NCT00674466 · Phase 2 · registry result, not featured evidence · converted to mmol/L from -5.88 mg/dL as posted
Weight -1.98 vs -1.58 placebo kg @ 12.14wk1.5 mg
absolute change · kg
NCT00638716 · Phase 2 · registry result, not featured evidence
show 1 more result
-1.17 vs -0.39 placebo kg @ 12.14wk1.5 mg
NCT00674466 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Albenatide's landscape · aleniglipron's landscape